Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Down 71.5% in January

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 19,386 shares, a decline of 71.5% from the January 15th total of 68,026 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average daily volume of 72,538 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 72,538 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the company’s shares are short sold.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors own 7.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Indaptus Therapeutics presently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

NASDAQ INDP traded down $0.03 during trading hours on Wednesday, reaching $1.79. 20,838 shares of the company’s stock traded hands, compared to its average volume of 87,618. Indaptus Therapeutics has a 52-week low of $1.52 and a 52-week high of $47.60. The firm has a 50-day simple moving average of $2.50 and a 200 day simple moving average of $3.70. The firm has a market cap of $4.00 million, a PE ratio of -0.06 and a beta of 0.98.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.17) by $1.19. Sell-side analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.